BofA lowered the firm’s price target on Revvity (RVTY) to $110 from $116 and keeps a Buy rating on the shares. The firm is updating its price targets for stocks under its coverage in the Life Sciences & Diagnostic Tools, LSTs, sector, the analyst tells investors. The firm notes LSTs remain under pressure as uncertainty persists with the macro environment and U.S. government policies. Recent weeks, however, have seen some signs of improvement as tariff concerns have cools slightly, the firm adds.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RVTY:
- Revvity announces launch of three Mimix reference standards for IVD use
- Citi adds ‘upside 90-day short-term view’ on Revvity
- Revvity upgraded to Buy from Neutral at UBS
- Revvity Reports Strong Q1 2025 Financial Results
- Revvity’s Resilience and Strategic Positioning Earns Buy Rating Amidst Macroeconomic Challenges